Anika Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results Fourth Quarter Revenue Increases 23% on Strong Sales of Orthovisc Earnings Grow 48% to $0.31 per Share in Quarter and 32% to $0.82 per Share for Year Business Wire BEDFORD, Mass. -- February 27, 2013 Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter and full year ended December 31, 2012. The company generated record quarterly and full year revenue in 2012. Management Commentary “In addition to achieving record quarterly and full year revenue, Anika delivered double-digit revenue and net income growth in the fourth quarter of 2012, concluding an excellent year from both financial and operational perspectives,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “These results were in line with the preliminary financial results we released on January 22, 2013.” “Our top-line performance continues to be driven by strong demand for Orthovisc, our flagship orthobiologics product,” Sherwood said. “Orthovisc revenue in our U.S. market was up nearly 42% for the full year. Through the strength of our partner Depuy Mitek’s marketing activities over the past year, Orthovisc closed 2012 as the market leader in the U.S. multi-injection segment and the number two U.S. brand in viscosupplementation overall. On the bottom line, growing revenue, coupled with operating efficiencies, have enabled us to drive continued growth in income from operations and generate robust cash flow. Our financial performance remains strong despite a one time restructuring charge in the fourth quarter implemented to strengthen our business and refocus our development programs.” “We have made progress in our efforts to secure U.S. regulatory approval for Monovisc^®,” said Sherwood. “Subsequent to our Monovisc announcement on December 4, 2012, we completed an encouraging discussion with the FDA in January 2013 to determine our next steps. We followed up on that discussion by submitting a new PMA amendment incorporating existing data.” “The year 2012 was successful for Anika, and we are well-positioned for further success in 2013,” Sherwood said. “Demand for Orthovisc is growing. We continue to streamline our operations and improve our manufacturing capabilities, and we are excited about our product pipeline. Anika is evolving from an HA biomaterials company into a products company focused on promising new medical solutions, and a company dedicated to capturing more of the value we have created by enhancing our capabilities in commercialization. We look forward to reporting our progress as the rest of 2013 unfolds.” Revenue Anika’s total revenue increased 23% to $22.6 million in the fourth quarter of 2012, from $18.4 million in the fourth quarter of 2011. For the full year 2012, total revenue grew 10% to $71.4 million, from $64.8 million a year earlier. The company’s revenue growth for both periods was primarily driven by increased sales of its flagship Orthobiologics product, Orthovisc^®. Product Gross Margin Product gross margin for the fourth quarter of 2012 improved to 66.1%, from 59.8% in the fourth quarter last year. For the 12 months ended December 31, 2012, product gross margin increased to 57.4%, compared with 56.8% for full year 2011. The improvements for both the quarter and the year were driven by higher production volume, a more favorable product mix, and the realization of operational efficiencies from our new manufacturing facility after consolidation of sites. Operating Income Operating income for the fourth quarter of 2012 increased to $7.8 million, from $4.9 million in the same period in 2011. For the 12 months ended December 31, 2012, operating income increased to $19.7 million, from $14.0 million a year earlier. This growth was driven by a combination of increased revenue, higher product gross profit, lower R&D spending related to clinical studies, and reduced general and administrative expenses in 2012. Net Income Net income for the fourth quarter of 2012 rose to $4.5 million, or $0.31 per diluted share, from $2.9 million, or $0.21 per diluted share, in the fourth quarter last year. For full year 2012, net income grew to $11.8 million, or $0.82 per diluted share, from $8.5 million, or $0.62 per diluted share, in 2011. Net income for both 2012 periods includes, a one-time, pre-tax charge of $2.5 million related to the closure of the company’s tissue engineering facility in Italy. The company’s effective tax rate for 2012 increased to 39.8%, from 38.6% for 2011. Operating Expenses Research and development expenses for the fourth quarter of 2012 were $1.3 million, compared with $1.5 million in the fourth quarter last year. For the full year, R&D expenses decreased to $5.4 million, from $6.2 million in 2011. Anika expects a significant year-over-year increase in R&D expense for 2013 due to the anticipated initiation of a clinical study and new product pipeline initiatives. Selling, general and administrative (“SG&A”) expenses in the fourth quarter of 2012 decreased to $3.7 million, from $4.9 million in the fourth quarter of 2011. For full year 2012, SG&A expenses decreased to $14.7 million, compared with $17.9 million in 2011. The declines for both periods were primarily due to U.S. manufacturing facilities consolidation, and the assumption of litigation costs by a third party. Cash and Cash Equivalents Anika’s cash and cash equivalents at December 31, 2012 increased to $44.1 million, from $35.8 million at December 31, 2011, driven by higher profits. Conference Call Information Anika will hold a conference call to discuss its financial results, business highlights and outlook tomorrow, Thursday, February 28, 2013 at 9:00 a.m. ET. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed. To listen to the conference call, dial 800-291-5365 (international callers dial 617-614-3922) and use the passcode 89264114. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available through a live audio webcast in the “Investor Relations” section of the Anika Therapeutics website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The conference call will be archived and accessible on the same website shortly after the conclusion of the call. About Anika Therapeutics, Inc. Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products range from orthopedic/joint health solutions led by Orthovisc, a treatment for osteoarthritis of the knee, to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika’s Italian subsidiary, Anika S.r.l., provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in areas such as advanced wound treatment and ear, nose and throat care. Anika S.r.l.’s regenerative tissue technology advances Anika’s vision to offer therapeutic products and medical solutions that go beyond pain relief to protect and restore damaged tissue. The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to:(i) our discussions with the FDA regarding U.S. regulatory approval of Monovisc, including the FDA’s decision regarding the recently submitted PMA amendment, and our abilities to obtain FDA approval for Monovisc, (ii) future demand for Orthovisc, (iii) the company’s plans to continue streamlining operations and improving its manufacturing capabilities, (iv) the prospects for the company’s product pipeline, and (v) expectations regarding research and development spending. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks, uncertainties and other factors. The company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including (i) the company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, obtain pre-clinical or clinical data to support a pre-market approval application or 510(k) application, or timely file and receive FDA or other regulatory approvals or clearances of its products, or that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (ii) the company's research and product development efforts and their relative success, including whether the company has any meaningful sales of any new products resulting from such efforts; (iii) the cost effectiveness and efficiency of our clinical studies, manufacturing operations and production planning; (iv) the strength of the economies in which the company operates or will be operating, as well as the political stability of any of those geographic areas; (v) future determinations by the company to allocate resources to products and in directions not presently contemplated, (vi) the company’s ability to launch Monovisc in the U.S., if at all; (vii) the company’s ability to provide an adequate and timely supply of its ophthalmic, Orthovisc and other products to its customers, (viii) our ability to successfully manage and turnaround Anika S.r.l.’s business, and (ix) the company’s ability to achieve its stated growth targets. Certain other factors that might cause the company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Annual Report on Form 10-K for the year ended December 31, 2011, as well as those described in the company's other press releases and SEC filings. Anika Therapeutics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2012 2011 % 2012 2011 % Product $ 21,459,124 $ 17,725,546 21 % $ 68,010,169 $ 61,956,386 10 % revenue Licensing, milestone and 1,147,341 718,741 3,348,336 2,822,249 contract revenue Total revenue 22,606,465 18,444,287 23 % 71,358,505 64,778,635 10 % Operating expenses: Cost of product 7,269,886 7,128,450 2 % 28,988,621 26,783,738 8 % revenue Research & 1,339,677 1,530,762 -12 % 5,388,036 6,168,937 -13 % development Selling, general & 3,667,406 4,869,290 -25 % 14,728,662 17,858,558 -18 % administrative Restructuring 2,537,988 - 2,537,988 - charge Total operating 14,814,957 13,528,502 10 % 51,643,307 50,811,233 2 % expenses Income from 7,791,508 4,915,785 58 % 19,715,198 13,967,402 41 % operations Interest income (42,284 ) (49,917 ) (187,777 ) (182,388 ) (expense), net Income before 7,749,224 4,865,868 59 % 19,527,421 13,785,014 42 % income taxes Provision for 3,286,001 1,982,758 7,769,961 5,318,334 income taxes Net income $ 4,463,223 $ 2,883,110 55 % $ 11,757,460 $ 8,466,680 39 % Basic net income per share: Net income $ 0.33 $ 0.22 $ 0.89 $ 0.65 Basic weighted average common 13,324,942 13,122,004 13,260,739 13,064,051 shares outstanding Diluted net income per share: Net income $ 0.31 $ 0.21 $ 0.82 $ 0.62 Diluted weighted average common 14,299,211 13,804,806 14,344,577 13,747,813 shares outstanding Anika Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets December 31, ASSETS 2012 2011 Current assets: Cash and cash equivalents $ 44,067,477 $ 35,777,222 Accounts receivable, net of reserves of $337,459 and $334,473 at December 21,462,481 17,307,786 31, 2012 and 2011, respectively Inventories 8,283,472 7,302,483 Current portion deferred income taxes 2,031,583 1,918,926 Prepaid expenses and other 1,539,477 1,831,127 Total current assets 77,384,490 64,137,544 Property and equipment, at cost 52,376,013 50,850,630 Less: accumulated depreciation (17,263,032 ) (14,380,752 ) 35,112,981 36,469,878 Long-term deposits and other 171,053 205,042 Intangible assets, net 20,334,636 23,148,563 Goodwill 9,065,891 8,883,407 Total Assets $ 142,069,051 $ 132,844,434 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,341,838 $ 4,299,680 Accrued expenses 5,837,044 5,321,594 Deferred revenue 2,875,067 2,866,667 Current portion of long-term debt 1,600,000 1,600,000 Income taxes payable 1,798,669 450,482 Total current liabilities 14,452,618 14,538,423 Other long-term liabilities 1,541,124 1,548,652 Long-term deferred revenue 2,152,778 5,019,440 Deferred tax liability 6,997,397 7,375,141 Long-term debt 8,000,000 9,600,000 Commitments and contingencies Stockholders’ equity: Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares - - issued and outstanding at December 31, 2012 and 2011, respectively Common stock, $.01 par value; 30,000,000 shares authorized, 13,866,060 and 13,630,607 shares 138,659 136,305 issued and outstanding at December 31, 2012 and 2011, respectively Additional paid-in-capital 65,431,424 63,441,433 Accumulated currency translation (2,654,630 ) (3,067,181 ) adjustment Retained earnings 46,009,681 34,252,221 Total stockholders’ equity 108,925,134 94,762,778 Total Liabilities and Stockholders’ $ 142,069,051 $ 132,844,434 Equity Anika Therapeutics, Inc. and Subsidiaries Supplemental Financial Data Revenue by Product Line Quarter Ended December 31, Year Ended December 31, 2012 % 2011 % 2012 % 2011 % Product Line: Orthobiologics $ 19,691,122 92 % $ 11,681,024 66 % $ 49,954,112 74 % $ 39,858,139 64 % Dermal 351,101 2 % 1,345,285 8 % 1,384,403 2 % 3,681,166 6 % Surgical 1,148,050 5 % 1,227,984 7 % 5,022,456 7 % 4,976,261 8 % Ophthalmic 268,851 1 % 2,918,619 16 % 8,784,011 13 % 10,963,822 18 % Veterinary - - % 552,634 3 % 2,865,187 4 % 2,476,998 4 % Total Product $ 21,459,124 100 % $ 17,725,546 100 % $ 68,010,169 100 % $ 61,956,386 100 % Revenue Product Gross Profit Margin Quarter Ended December 31, Year Ended December 31, 2012 % 2011 % 2012 % 2011 % Product gross $ 14,189,238 66.1 % $ 10,597,096 59.8 % $ 39,021,548 57.4 % $ 35,172,648 56.8 % profit Product Revenue by Geographic Location Quarter Ended December 31, Year Ended December 31, 2012 % 2011 % 2012 % 2011 % Geographic Location: United States $ 16,792,632 78 % $ 12,480,149 71 % $ 55,063,559 81 % $ 45,652,253 74 % Europe 2,119,867 10 % 3,401,434 19 % 6,148,345 9 % 10,865,628 17 % Other 2,546,625 12 % 1,843,963 10 % 6,798,265 10 % 5,438,505 9 % Total Product $ 21,459,124 100 % $ 17,725,546 100 % $ 68,010,169 100 % $ 61,956,386 100 % Revenue Contact: Anika Therapeutics, Inc. Charles H. Sherwood, Ph.D., 781-457-9000 CEO
Anika Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
Press spacebar to pause and continue. Press esc to stop.